Logo

QURE

uniQure N.V.

QURE

uniQure N.V. • NASDAQ
$27.51 ▼ -0.43% (-0.12)
Market Cap $1.49 B
52w High $71.50
52w Low $6.11
Dividend Yield 0%
P/E -6.25
Volume 436.52K
Outstanding Shares 54.13M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.701M ▼ $54.338M ▲ $-80.529M ▼ -2.176K% ▼ $-1.38 ▼ $-51.55M ▼
Q2-2025 $5.262M ▲ $48.471M ▲ $-37.719M ▲ -716.819% ▲ $-0.69 ▲ $-18.073M ▲
Q1-2025 $1.567M ▼ $40.701M ▼ $-43.637M ▲ -2.785K% ▼ $-0.82 ▲ $-23.505M ▲
Q4-2024 $5.221M ▲ $50.43M ▲ $-73.261M ▼ -1.403K% ▲ $-1.5 ▼ $-53.173M ▼
Q3-2024 $2.287M $41.494M $-44.378M -1.94K% $-0.91 $-24.812M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $694.245M ▲ $888.382M ▲ $659.636M ▲ $228.746M ▲
Q2-2025 $376.974M ▼ $584.89M ▼ $588.893M ▲ $-4.003M ▼
Q1-2025 $409.011M ▲ $605.403M ▲ $571.717M ▲ $33.686M ▲
Q4-2024 $367.521M ▼ $556.536M ▼ $563.288M ▼ $-6.752M ▼
Q3-2024 $435.241M $645.806M $589.985M $55.821M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-80.529M ▼ $-16.399M ▲ $26.579M ▼ $332.235M ▲ $343.277M ▲ $-16.333M ▲
Q2-2025 $-37.719M ▲ $-39.895M ▲ $73.073M ▲ $44K ▼ $36.614M ▼ $-40.155M ▲
Q1-2025 $-43.637M ▲ $-44.1M ▲ $20.099M ▲ $80.67M ▲ $58.329M ▲ $-44.226M ▲
Q4-2024 $-73.261M ▼ $-52.844M ▼ $-26.624M ▼ $-6.517M ▲ $-92.75M ▼ $-52.905M ▼
Q3-2024 $-44.378M $-36.598M $47.67M $-53.019M $-37.96M $-45.278M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Collaboration revenues
Collaboration revenues
 $0 ▲$0 ▲$0 ▲$0 ▲
License revenues
License revenues
 $0 ▲$0 ▲$10.00M ▲$0 ▼

Five-Year Company Overview

Income Statement

Income Statement Revenue has been very small and uneven over the past few years, with what looks like a one‑off revenue spike earlier in the period and only modest income since then. The business is still firmly in the investment phase: operating losses are recurring, and net losses have widened again more recently after a briefly profitable year in the middle of the period. In plain terms, the company is still spending much more on research, operations, and overhead than it brings in from partnerships or product‑related income.

Balance Sheet

Balance Sheet The balance sheet has gradually shrunk from its earlier peak, with total assets and cash both moving down over time. Cash remains a meaningful portion of assets, but it has declined, reflecting continued cash burn. Debt is present but not excessive relative to the company’s size. The more concerning signal is that shareholder equity has eroded and recently slipped slightly negative, indicating accumulated losses have essentially consumed the company’s book value. This puts more importance on future financing and partnership support.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative except for one strong year when the company likely benefited from significant milestone or collaboration inflows. Since then, operating cash burn has resumed and stayed fairly steady. Free cash flow is also negative, although capital spending is relatively modest, so most of the cash outflow is driven by ongoing R&D and operating costs rather than big one‑time investments. Overall, the company is reliant on external funding sources and partnership revenues to sustain its pipeline until it can generate more stable commercial cash flows.

Competitive Edge

Competitive Edge uniQure holds a differentiated position in gene therapy, supported by its specialized AAV platform, long experience in the field, and a high‑profile product in hemophilia B partnered with a larger commercial player. Its intellectual property around vectors, manufacturing processes, and key programs like Huntington’s disease provides a real, though not unassailable, moat. The sale of its manufacturing facility in exchange for a strategic supply relationship shifts it toward a more asset‑light model, but also increases reliance on partners. The company still competes in a crowded and fast‑moving gene therapy space against well‑funded biotech and pharma players, and its ultimate competitive strength will depend on clinical outcomes, safety profiles, pricing, and payer acceptance of its therapies.

Innovation and R&D

Innovation and R&D Innovation is the core of uniQure’s story. It has built a versatile gene therapy toolkit, including proprietary vectors and gene‑silencing technologies, aimed particularly at neurological and rare genetic diseases. The hemophilia B therapy validates its platform, while the Huntington’s disease program stands out as a potential landmark if later‑stage data and regulatory discussions hold up. Beyond these, the pipeline spans several high‑need conditions, from ALS and epilepsy to genetic forms of Alzheimer’s and Fabry disease. This breadth offers multiple shots on goal, but each program carries substantial scientific, regulatory, and commercial risk, and advancing them will require continued heavy R&D spending and careful prioritization.

Summary

uniQure is a classic high‑innovation, high‑risk biotech: scientifically ambitious, financially loss‑making, and highly dependent on successful execution of a few key programs and partnerships. The income statement and cash flows show a company still far from self‑funding, with ongoing losses and sustained cash burn. The balance sheet, while still supported by a meaningful cash position, shows pressure from cumulative losses and now slightly negative equity, increasing the importance of future financing and partner support. On the positive side, the company’s technology platform, intellectual property, and early commercial validation in hemophilia B give it a real foothold in gene therapy, and its Huntington’s disease program could be transformative if it progresses as hoped. Overall, the story hinges less on current financial strength and more on whether its scientific and regulatory milestones can convert into durable, cash‑generating products before financial flexibility tightens further.

NEWS

November 28, 2025 · 11:46 AM UTC

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Read more

November 24, 2025 · 5:20 PM UTC

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Read more

November 22, 2025 · 11:40 AM UTC

QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Read more

November 20, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE

Read more

November 14, 2025 · 12:29 PM UTC

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Read more